RESUMO
OBJECTIVE:To review the current situation and the trend of development of drugs for chronic hepatic diseases,so as to provide the information for rational use of these drugs METHODS:By using the methods of sequences of total sales volumn and DDDs,the main drugs for chronic hepatic diseases used in 8 hospitals of Xinxiang during the period 2001～2003 were analysed RESULTS & CONCLUSION:The total sales volumn and DDDs of the liver-protective drugs always occupied the front row of drugs for chronic hepatic diseases,and the use of compound glycyrrihizin(Stronger Neo-Minophagen C) is rapidly increasing
RESUMO
OBJECTIVE:To observe the hepatoprotective effect of compound glycyrrhizin in treating patients with multidrug resistant pulmonary tuberculosis(MDR-TB).METHODS:A total of 68 MDR-TB cases were enrolled:36(treatment group) were randomly assigned to receive additional glycyrrhizin,and 32(control group) to receive additional glucurolactone and legalon,the hepatoprotective effects and side effects between 2 groups were compared before and after treatment.RESULTS:The total effective rates of the treatment group and the control group were 94.4% and 62.5%,respectively 1month after hepatoprotective treatment,and significant difference was noted between 2 groups(P0.05).CONCLUSION:Compound glycyrrhizin has a reliable hepatoprotective efficacy and few adverse drug reactions in treating MDR-TB patients complicating with lesion of liver function.